Meribank Biotech Co., Ltd

NT$8.88As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4724Healthcare
Country Taiwan
PE (Fwd) •••
TSR 3Y CAGR (39.56%)
Div yield —
ROE (11.33%)
Biotechnology
Beta (5Y) 0.41
PE TTM —
TSR TTM (50.80%)
Mkt cap NT$852.3M
ROIC (2.86%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$10
13.08%
(93.17%)
Hold 7|2|1|8|0
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.10
0.10
0.10
0.11
11.80%
9.02%
3.88%
12.63%
RevenueNT$M
46.89
45.72
47.49
48.69
6.26%
0.47%
2.94%
5.75%
Peers (US$24.67M)
Cap (US$)
PE
24.67M
—
Capital
TTM
5Y
10Y
Leveragex
0.059
0.636
0.446
EBIT/Intx
2.312
0.103
0.117
Own earn%
377.51
(93.50)
(89.47)
Sh yield%
48.63
18.66
19.39
Owners
Insiders/Inst%
8.26
80.81
Short interest%
1.32
SBC / revenue%
1.38
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
0–4
$1 testx
—
Incr. ROIC%
12